“This patient population has a higher risk of cardiovascular death, heart attack ... cleared for obesity in adults in 2021 and had its label extended in 2022 to include adolescents aged 12 ...
Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback